{{ 'fb_in_app_browser_popup.desc' | translate }} {{ 'fb_in_app_browser_popup.copy_link' | translate }}
{{ 'in_app_browser_popup.desc' | translate }}
{{ childProduct.title_translations | translateModel }}
{{ getChildVariationShorthand(childProduct.child_variation) }}
{{ getSelectedItemDetail(selectedChildProduct, item).childProductName }} x {{ selectedChildProduct.quantity || 1 }}
{{ getSelectedItemDetail(selectedChildProduct, item).childVariationName }}
pregnant women from week 10 of pregnancy
Not enough stock.
Your item was not added to your cart.
Not enough stock.
Please adjust your quantity.
{{'products.quick_cart.out_of_number_hint'| translate}}
{{'product.preorder_limit.hint'| translate}}
Limit {{ product.max_order_quantity }} per order.
Only {{ quantityOfStock }} item(s) left.
utilizes Next Generation Sequencing technique and bioinformatics analysis on both maternal DNA and cell free placental DNA found in maternal blood. Compared to traditional screening methods based on nuchal translucency or maternal age,
is more sensitive,reliable, accurate and informative.
During pregnancy, the fetus releases some of the cell-free DNA into the blood circulation of its mother.
DNA from the fetus is obtained by drawing 10mL of maternal blood.
Safe T21 express analyses the circulating cell-free DNA molecules by NGS technology followed by bioinformatics analysis.
The report containing the genetic information of the fetus will be available in 5 working days.